Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with decarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response

This publication has 21 references indexed in Scilit:

• Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.
  Journal of Clinical Oncology, 1991
• Cutaneous Melanoma
  New England Journal of Medicine, 1991
• Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial.
  Journal of Clinical Oncology, 1991
• A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.
  Journal of Clinical Oncology, 1991
• Recombinant Interleukin-2 and Adoptive Immunotherapy Alternated With Dacarbazine Therapy in Melanoma: A National Biotherapy Study Group Trial
  JNCI Journal of the National Cancer Institute, 1990
• A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma
  Cancer, 1990
• Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
  Annals of Surgery, 1989
• Adoptive Immunotherapy in Combination with Chemotherapy for Cancer Treatment
  Published by S. Karger AG ,1987
• Interleukin 1 inhibitory activity secreted by a human myelomonocytic cell line (M20)
  European Journal of Immunology, 1986
• A rapid technique for isolation of viable tumor cells from solid tumors: Use of the tumor cells for induction and measurement of cell-mediated cytotoxic responses
  European Journal of Cancer and Clinical Oncology, 1982